Abstract
This study examined D-amphetamine (D-AMPH)-induced displacements of [18F] fallypride in striatal and extrastriatal regions and the correlations of these displacements with cognition, affect, and sensation-seeking behavior. In all, 14 normal subjects, six females and eight males (ages 21–32, mean age 25.9 years), underwent positron emission tomography (PET) with [18F]fallypride before and 3 h after a 0.43 mg/kg oral dose of D-AMPH. Levels of dopamine (DA) D2 receptor density were calculated with the reference region method of Lammerstma. Percent displacements in striatal and extrastriatal regions were calculated for the caudate, putamen, ventral striatum, medial thalamus, amygdala, substantia nigra, and temporal cortex. Correlations of changes in cognition, affect, and sensation seeking with parametric images of D-AMPH-induced DA release were computed. Significant displacements were seen in the caudate, putamen, ventral striatum substantia nigra, and temporal cortex with a trend level change in the amygdala. Greatest displacements were seen in striatal subdivisions—5.6% in caudate, 11.2% in putamen, 7.2% in ventral striatum, and 6.6% in substantia nigra. Lesser decrements were seen in amygdala—4.4%, temporal cortex—3.7%, and thalamus—2.8%. Significant clusters of correlations of regional DA release with cognition and sensation-seeking behavior were observed. The current study demonstrates that [18F]fallypride PET studies using oral D-AMPH (0.43 mg/kg) can be used to study D-AMPH-induced DA release in the striatal and extrastriatal regions in humans, and their relationship with cognition and sensation-seeking behavior.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Aalto S, Bruck A, Laine M, Nagren K, Rinne JO (2005). Frontal and temporal dopamine release during working memory and attention tasks in healthy humans: a positron emission tomography study using the high-affinity dopamine D2 receptor ligand [11C] FLB457. J Neurosci 25: 2471–2477.
Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M et al (1998). Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155: 761–767.
Abi-Dargham A, Kegeles LS, Martinez D, Innis RB, Laruelle M (2003). Dopamine mediation of positive reinforcing effects of amphetamine in stimulant naive healthy volunteers: results from a large cohort. Eur Neuropsychopharmacol 13: 459–468.
Abi-Dargham A, Kegeles LS, Zea-Ponce Y, Mawlawi O, Martinez D, Mitropoulou V et al (2004). Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol Psychiatry 55: 1001–1006.
al-Tikriti MS, Baldwin RM, Zea-Ponce Y, Sybirska E, Zoghbi SS, Laruelle M et al (1994). Comparison of three high affinity SPECT radiotracers for the dopamine D2 receptor. Nucl Med Biol 21: 179–188.
Angrist B, Corwin J, Bartlik B, Cooper T (1987). Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects. Biol Psychiatry 22: 1357–1368.
Bigliani V, Mulligan RS, Acton PD, Ohlsen RI, Pike VW, Ell PJ et al (2000). Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berlin) 150: 132–140.
Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A et al (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci USA 94: 2569–2574.
Bressan RA, Erlandsson K, Jones HM, Mulligan RS, Ell PJ, Pilowsky LS (2003). Optimizing limbic selective D2/D3 receptor occupancy by risperidone: a [123I]-epidepride SPET study. J Clin Psychopharmacol 23: 5–14.
Campins-Falco P, Sevillano-Cabeza A, Molins-Legua C, Kohlmann M (1996). Amphetamine and methamphetamine determination in urine by reversed-phase high-performance liquid chromatography with simultaneous sample clean-up and derivatization with 1,2-naphthoquinone 4-sulphonate on solid-phase cartridges. J Chromatogr B Biomed Appl 687: 239–246.
Cardenas L, Houle S, Kapur S, Busto UE (2004). Oral D-amphetamine causes prolonged displacement of [11C]raclopride as measured by PET. Synapse 51: 27–31.
Chou YH, Halldin C, Farde L (2000). Effect of amphetamine on extrastriatal D2 dopamine receptor binding in the primate brain: a PET study. Synapse 38: 138–143.
Christian BT, Narayanan T, Shi B, Morris ED, Mantil J, Mukherjee J (2004). Measuring the in vivo binding parameters of [18F]-fallypride in monkeys using a PET multiple-injection protocol. J Cereb Blood Flow Metab 24: 309–322.
Cragg SJ, Greenfield SA (1997). Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum. J Neurosci 17: 5738–5746.
Cragg SJ, Nicholson C, Kume-Kick J, Tao L, Rice ME (2001). Dopamine-mediated volume transmission in midbrain is regulated by distinct extracellular geometry and uptake. J Neurophysiol 85: 1761–1771.
Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA et al (2001). Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol Psychiatry 49: 81–96.
Endres CJ, Carson RE (1998). Assessment of dynamic neurotransmitter changes with bolus or infusion delivery of neuroreceptor ligands. J Cereb Blood Flow Metab 11: 1196–1210.
Falkenburger BH, Barstow KL, Mintz IM (2001). Dendrodendritic inhibition through reversal of dopamine transport. Science 293: 2407–2409.
Farde L, Suhara T, Nyberg S, Karlsson P, Nakashima Y, Hietala J et al (1997). A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology 133: 396–404.
Forman SD, Cohen JD Fitzgerald M, Eddy WF, Mintun MA, Noll DC (1995). Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): use of a cluster-size threshold. Magn Reson Med 33: 636–647.
Fujita M, Seibyl JP, Verhoeff NP, Ichise M, Baldwin RM, Zoghbi SS et al (1999). Kinetic and equilibrium analyses of [(123)I]epidepride binding to striatal and extrastriatal dopamine D(2) receptors. Synapse 34: 290–304.
Fuxe K, Rivera A, Jacobsen KX, Hoistad M, Leo G, Horvath TL et al (2005). Dynamics of volume transmission in the brain. Focus on catecholamine and opioid peptide communication and the role of uncoupling protein 2. J Neural Transm 112: 65–76.
Garris PA, Wightman RM (1994). Different kinetics govern dopaminergic transmission in the amygdala, prefrontal cortex, and striatum: an in vivo voltammetric study. J Neurosci 14: 442–450.
Gerhardt GA, Cass WA, Yi A, Zhang Z, Gash DM (2002). Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J Neurochem 80: 168–177.
Ginovart N, Farde L, Halldin C, Swahn CG (1997). Effect of reserpine-induced depletion of synaptic dopamine on [11C]raclopride binding to D2-dopamine receptors in the monkey brain. Synapse 25: 321–325.
Goldman-Rakic P (1998). The cortical dopamine system: role in memory and cognition. Adv Pharmacol 42: 707–711.
Hall H, Ogren SO, Kohler C, Magnusson O (1989). Animal pharmacology of raclopride, a selective dopamine D2 antagonist. Psychopharmacol Ser 7: 123–130.
Halldin C, Farde L, Hogberg T, Mohell N, Hall H, Suhara T et al (1995). Carbon-11-FLB 457: a radioligand for extrastriatal D2 dopamine receptors. J Nucl Med 36: 1275–1281.
Heeringa MJ, Abercrombie ED (1995). Biochemistry of somatodendritic dopamine release in substantia nigra: an in vivo comparison with striatal dopamine release. J Neurochem 65: 192–200.
Hooks MS, Juncos JL, Justice Jr JB, Meiergerd SM, Povlock SL, Schenk JO et al (1994). Individual locomotor response to novelty predicts selective alterations in D1 and D2 receptors and mRNAs. J Neurosci 14: 6144–6152.
Kaasinen V, Nurmi E, Bergman J, Eskola O, Solin O, Sonninen P et al (2001). Personality traits and brain dopaminergic function in Parkinson's disease. Proc Natl Acad Sci USA 98: 13272–13277.
Kegeles LS, Zea-Ponce Y, Abi-Dargham A, Rodenhiser J, Wang T, Weiss R et al (1999). Stability of [123I]IBZM SPECT measurement of amphetamine-induced striatal dopamine release in humans. Synapse 31: 302–308.
Kerwin RW, Murray RM (1992). A developmental perspective on the pathology and neurochemistry of the temporal lobe in schizophrenia. Schizophr Res 7: 1–12.
Kessler RM, Ansari MS, Li R, Lee M, Schimdt D, Dawant B et al (2002). Occupancy of cortical and substantia nigra DA D2 receptors by typical and atypical antipsychotic drugs. Neuroimage 16: S9.
Kessler RM, Ansari MS, Schmidt DE, de Paulis T, Clanton JA, Innis R et al (1991). High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors. Life Sci 49: 617–628.
Kessler RM, Mason NS, Votaw JR, De Paulis T, Clanton JA, Ansari MS et al (1992). Visualization of extrastriatal dopamine D2 receptors in the human brain. Eur J Pharmacol 223: 105–107.
Kessler RM, Votaw JR, de Paulis T, Bingham DR, Ansari MS, Mason NS et al (1993a). Evaluation of 5-[18F] fluoropropylepidepride as a potential PET radioligand for imaging dopamine D2 receptors. Synapse 5: 169–176.
Kessler RM, Votaw JR, Schmidt DE, Ansari MS, Holdeman KP, de Paulis T et al (1993c). High affinity dopamine D2 receptor radioligands. 3. [123I] and [125I]epidepride: in vivo studies in rhesus monkey brain and comparison with in vitro pharmacokinetics in rat brain. Life Sci 53: 241–250.
Kessler RM, Whetsell WO, Ansari MS, Votaw JR, de Paulis T, Clanton JA et al (1993b). Identification of extrastriatal dopamine D2 receptors in post mortem human brain with [125I]epidepride. Brain Res 609: 237–243.
Koob GF, Le Moal M (2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24: 97–129.
Kung HF, Pan S, Kung MP, Billings J, Kasliwal R, Reilley J et al (1989). In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med 30: 88–92.
Lammertsma AA, Bench CJ, Hume SP, Osman S, Gunn K, Brooks DJ et al (1996). Comparison of methods for analysis of clinical [11C]raclopride studies. J Cereb Blood Flow Metab 16: 42–52.
Laruelle M (2000). Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20: 423–451.
Laruelle M, Abi-Dargham A, van Dyck CH, Gil R, D'Souza CD, Erdos J et al (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93: 9235–9240.
Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS et al (1995). SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36: 1182–1190.
Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS et al (1997). Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 25: 1–14.
Lavely WC, Scarfone C, Cevikalp H, Li R, Byrne DW, Cmelak AJ et al (2004). Phantom validation of coregistration of PET and CT for image-guided radiotherapy. Med Phys 31: 1083–1092.
Lawrence AD, Weeks RA, Brooks DJ, Andrews TC, Watkins LH, Harding AE et al (1998). The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease. Brain 121: 1343–1355.
Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, Dagher A (2002). Amphetamine-induced increases in extracellular dopamine, drug wating, and novelty seeking: a PET [11C] raclopride study in healthy men. Neuropsychopharmacology 27: 1027–1035.
Marinelli M, White FJ (2000). Enhanced vulnerability to cocaine self-administration is associated with elevated impulse activity of midbrain dopamine neurons. J Neurosci 20: 8876–8885.
Martinez D, Slifstein M, Broft A, Mawlawi O, Hwang DR, Huang Y et al (2003). Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II: amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23: 285–300.
Mawlawi O, Martinez D, Slifstein M, Broft A, Chatterjee R, Hwang DR et al (2001). Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D(2) receptor parameter measurements in ventral striatum. J Cereb Blood Flow Metab 21: 1034–1057.
Mehta MA, Sahakian BJ, McKenna PJ, Robbins TW (1999). Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease. Psychopharmacology 146: 162–174.
Moghaddam B, Berridge CW, Goldman-Rakic PS, Bunney BS, Roth RH (1993). In vivo assessment of basal and drug-induced dopamine release in cortical and subcortical regions of the anesthetized primate. Synapse 13: 215–222.
Mukherjee J, Christian B, Shi B, Narayanan TK, Mantil J (2002). 18F-fallypride displacement in the non- human primate brain by nicotine- induced and amphetamine-induced dopamine release. Neuroimage 16: S42.
Mukherjee J, Christian BT, Dunigan KA, Shi B, Narayanan TK, Satter M et al (2002). Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test–retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse 46: 170–188.
Mukherjee J, Yang ZY, Brown T, Lew R, Wernick M, Ouyang X et al (1999). Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl Med Biol 26: 519–527.
Mukherjee J, Yang ZY, Das MK, Brown T (1995). Fluorinated benzamide neuroleptics. III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl Med Biol 22: 283–296.
Mukherjee J, Yang ZY, Lew R, Brown T, Kronmal S, Cooper MD et al (1997). Evaluation of D-amphetamine effects on the binding of dopamine D-2 receptor radioligand, 18F-fallypride in nonhuman primates using positron emission tomography. Synapse 27: 1–13.
Narendran R, Hwang DR, Slifstein M, Talbot PS, Erritzoe D, Huang Y et al (2004). In vivo vulnerability to competition by endogenous dopamine: comparison of the D2 receptor agonist radiotracer (−)-N-[11C]propylnorapomorphine ([11C]NPA) with the D2 receptor antagonist radiotracer [11C]-raclopride. Synapse 52: 188–208.
Okauchi T, Suhara T, Maeda J, Kawabe K, Obayashi S, Suzuki K (2001). Effect of endogenous dopamine on endogenous dopamine on extrastriated [(11)C]FLB 457 binding measured by PET. Synapse 41: 87–95.
Olsson H, Halldin C, Farde L (2004). Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. Neuroimage 22: 794–803.
Olsson H, Halldin C, Swahn CG, Farde L (1999). Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J Cereb Blood Flow Metab 19: 1164–1173.
Park S, Püschel J, Sauter B, Rentsch M, Hell D (1999). Spatial working memory deficits and clinical symptoms in schizophrenia; a 4-month follow-up study. Biol Psychiatry 46: 392–400.
Piazza PV, Rouge-Pont F, Deminiere JM, Kharoubi M, Le Moal M, Simon H (1991). Dopaminergic activity is reduced in the prefrontal cortex and increased in the nucleus accumbens of rats predisposed to develop amphetamine self-administration. Brain Res 567: 169–174.
Piccini P, Pavese N, Brooks DJ (2003). Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol 53: 647–653.
Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW (1997). Limbic selectivity of clozapine. Lancet 350: 490–491.
Pluim JPW, Maintz JBA, Viergever MA (2001). Mutual information matching in multiresolution context. Image Vision Comput 19: 45–52.
Price JC, Drevets WC, Ruszkiewicz J, Greer PJ, Villemagne VL, Xu L et al (2002). Sequential H(2)(15)O PET studies in baboons: before and after amphetamine. J Nucl Med 43: 1090–1100.
Riccardi P, Zald D, Li R, Park S, Ansari AS, Dawant B et al (2005). Sex differences in amphetamine induced displacement of [18F] fallypride in striatal and extrastriatal regions: a PET study. Am J Psychiatry, in press.
Rieck RW, Ansari MS, Whetsell Jr WO, Deutch AY, Kessler RM (2004). Distribution of dopamine D2-like receptors in the human thalamus: autoradiographic and PET studies. Neuropsychopharmacology 29: 362–372.
Rogers D (1986). Bradyphrenia in parkinsonism: a historical review. Psychol Med 16: 257–266.
Rohde GK, Aldroubi A, Dawant BM (2003). The adaptive bases algorithm for intensity based nonrigid registration. IEEE Trans Med Imaging 22: 1470–1479.
Sawaguchi T, Goldman-Rakic PS (1991). D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251: 947–950.
Schaltenbrand G, Wahren W (1977). Atlas for Stereotaxy of the Human Brain. Yearbook Medical Publisher, Inc.: Chicago.
Sesack SR, Aoki C, Pickel VM (1994). Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. J Neurosci 14: 88–106.
Shah PJ, Ogilvie AD, Goodwin GM, Ebmeier KP (1997). Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med 27: 1247–1256.
Singer HS, Szymanski S, Giuliano J, Yokoi F, Dogan AS, Brasic JR et al (2002). Elevated intrasynaptic dopamine release in Tourette's syndrome measured by PET. Am J Psychiatry 159: 1329–1336.
Slifstein M, Narendran R, Hwang DR, Sudo Y, Talbot PS, Huang Y et al (2004). Effect of amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: single bolus and bolus plus constant infusion studies. Synapse 54: 46–63.
Stevens JR (1991). Psychosis and the temporal lobe. Adv Neurol 55: 79–96.
Stoelting Co (2000). The Stroop Color and Word Test. Stoelting Co.: Wood Dale, IL.
Suhara T, Okubo Y, Yasuno F, Sudo Y, Inoue M, Ichimiya T et al (2002). Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch Gen Psychiatry 59: 25–30.
Talvik M, Nordstrom AL, Nyberg S, Olsson H, Halldin C, Farde L (2001). No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am J Psychiatry 158: 926–930.
Townsend DW, Isoardi RA, Bendriem B (1998). Volume Imaging Tomographs. In: Bendriem B, Townsend DW (eds). The Theory and Practice of 3D PET. Kluwer Academic Publisher: Boston.
Tsukada H, Miyasato K, Kakiuchi T, Nishiyama S, Harada N, Domino EF (2002). Comparative effects of methamphetamine and nicotine on the striatal [(11)C]raclopride binding in unanaesthetized monkeys. Synapse 45: 207–212.
Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N (1999a). Is synaptic dopamine concentration the exclusive factor which alters the in vivo binding of [11C]raclopride? PET studies combined with microdialysis in conscious monkeys. Brain Res 841: 160–169.
Tsukada H, Nishiyama S, Kakiuchi T, Ohba H, Sato K, Harada N et al (1999b). Isoflurane anesthesia enhances the inhibitory effects of cocaine and GBR12909 on dopamine transporter: PET studies in combination with microdialysis in the monkey brain. Brain Res 849: 85–96.
Volkow ND, Fowler JS, Wang GJ, Swanson JM (2004). Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 9: 557–569.
Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R et al (1994). Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 16: 255–262.
Watson D, Clark LA, Tellegen A (1988). Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 54: 1063–1070.
Wechsler D (1997). Wechsler Adult Intelligence Scale, 3rd edn. The Psychological Corporation, Harcourt Brace Jovanovich: San Antonio.
Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK et al (2001). Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50: 825–844.
West J, Fitzpatrick JM, Wang Y, Dawant BM, Maurer Jr CJ, Kessler RM et al (1997). Comparison and evaluation of retrospective intermodality image registration techniques. J Comput Assis Tomogr 21: 554–566.
Williams JB, Gibbon M, First MB, Spitzer RL, Davies M, Borus J et al (1992). The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test–retest reliability. Arch Gen Psychiatry 49: 630–636.
Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loch C et al (2001a). In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 21: 207–214.
Xiberas X, Martinot JL, Mallet L, Artiges E, Loc HC, Maziere B et al (2001b). Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br J Psychiatry 179: 503–508.
Yasuno F, Suhara T, Okubo Y, Sudo Y, Inoue M, Ichimiya T et al (2004). Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am J Psychiatry 161: 1016–1022.
Yung KK, Bolam JP, Smith AD, Hersch SM, Ciliax BJ, Levey AI (1995). Immunocytochemical localization of D1 and D2 receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 65: 709–730.
Zuckerman M, Eysenck S, Eysenck HJ (1978). Sensation seeking in England and America: cross-cultural, age, and sex comparisons. J Consult Clin Psychol 46: 139–149.
Acknowledgements
Funding for this research was provided by a NIH grant entitled, ‘PET Imaging of Extrastriatal Dopamine Levels’, NIMH 5R01 MH60898-03. We wish to thank Janine Belote, Michelle Costner, and Sarah Moore for technical assistance, and Joann Fields for her excellent assistance in the preparation of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Riccardi, P., Li, R., Ansari, M. et al. Amphetamine-Induced Displacement of [18F] Fallypride in Striatum and Extrastriatal Regions in Humans. Neuropsychopharmacol 31, 1016–1026 (2006). https://doi.org/10.1038/sj.npp.1300916
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1300916
Keywords
This article is cited by
-
Dopaminergic Plasticity in the Bilateral Hippocampus Following Threat Reversal in Humans
Scientific Reports (2020)
-
In vivo long-lasting alterations of central serotonin transporter activity and associated dopamine synthesis after acute repeated administration of methamphetamine
EJNMMI Research (2019)
-
The effects of ketamine on dopaminergic function: meta-analysis and review of the implications for neuropsychiatric disorders
Molecular Psychiatry (2018)
-
Automation of the Radiosynthesis of Six Different 18F-labeled radiotracers on the AllinOne
EJNMMI Radiopharmacy and Chemistry (2017)
-
No evidence for attenuated stress-induced extrastriatal dopamine signaling in psychotic disorder
Translational Psychiatry (2015)
